Stada Launches Bevacizumab Biosimilar In EU
Avastin Rival Oyavas Introduced In Germany And The Netherlands
Stada has launched its Oyavas version of bevacizumab upon EU approval, initially rolling out the oncology biosimilar in Germany and the Netherlands with other countries to follow.
You may also be interested in...
Stada and Xbrane have celebrated an endorsement from the EMA’s CHMP for their Ximluci ranibizumab biosimilar rival to Lucentis. The development follows a setback for a parallel filing in the US.
Stada has launched abiraterone film-coated tablets, a generic version of Janssen’s Zytiga, in 21 markets across Europe as protection for the branded treatment for metastatic prostate cancer expired.
Celltrion has received a positive opinion from the EMA’s CHMP for its Vegzelma bevacizumab biosimilar rival to Avastin, setting up the Korean firm to enter a competitive European market that already includes several bevacizumab biosimilars.